The estimated Net Worth of Somu Subramaniam is at least $762 Tausend dollars as of 11 March 2015. Somu Subramaniam owns over 50,762 units of Icad Inc stock worth over $293,425 and over the last 14 years Somu sold ICAD stock worth over $468,533.
Somu has made over 1 trades of the Icad Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Somu sold 50,762 units of ICAD stock worth $468,533 on 11 March 2015.
The largest trade Somu's ever made was selling 50,762 units of Icad Inc stock on 11 March 2015 worth over $468,533. On average, Somu trades about 1,952 units every 0 days since 2010. As of 11 March 2015 Somu still owns at least 211,097 units of Icad Inc stock.
You can see the complete history of Somu Subramaniam stock trades at the bottom of the page.
Somu's mailing address filed with the SEC is 98 Spit Brook Rd #100, Nashua, NH 03062, USA.
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton und Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Icad Inc executives and other stock owners filed with the SEC include: